The work centers on OPA1, a mitochondrial fusion protein whose loss in brown adipocytes triggers a cascade of stress responses. In earlier studies, the group led by Renata O. Pereira found that deleting OPA1 selectively in brown fat activates the transcription factor ATF4, which in turn ramps up production of two secreted signaling molecules: fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15). Both act as so-called batokines, hormones released by brown adipose tissue that travel through the circulation to influence metabolism elsewhere in the body. Mice lacking OPA1 in brown fat resist diet-induced obesity, burn more energy, and tolerate cold exposure remarkably well. But a key question remained open: which of these effects actually require GDF15 to act on its known receptor, GFRAL?

GDF15 is a divergent member of the TGF-β superfamily, a cytokine produced by nearly every cell type in response to stress. Its concentrations rise in the blood during aging, pregnancy, cancer, obesity, and cardiovascular disease, and its reputation as a regulator of appetite and body weight has made it one of the most closely watched molecules in metabolic research. In 2017, several research groups independently identified GFRAL, the GDNF family receptor α-like protein, as the receptor responsible for GDF15’s effects. GFRAL is expressed almost exclusively in discrete regions of the hindbrain, including the area postrema and the nucleus of the solitary tract, where GDF15 binding activates the GDF15-GFRAL-RET complex and suppresses food intake while increasing energy expenditure.

To test whether this brainstem pathway was truly responsible for the metabolic rewiring seen in the brown-fat stress model, the Iowa team, including first author Ayushi Sood, crossed OPA1 brown-fat knockout mice with mice lacking GFRAL throughout the body. The resulting double knockouts, which the researchers call DKO mice, lacked both the mitochondrial fusion protein in brown adipocytes and the GDF15 receptor in the hindbrain. The experiment provided a clean genetic test of whether GFRAL-dependent signaling was necessary for the improved metabolism previously attributed to GDF15.

At the molecular level, the cross worked exactly as designed. OPA1 mRNA was markedly reduced in brown fat of both the single and double knockouts, while Gfral mRNA was depleted from the hindbrain of mice carrying the GFRAL deletion. Importantly, deleting GFRAL did not interfere with the upstream induction of the stress response: Fgf21 and Gdf15 mRNA levels in brown fat rose in both OPA1 BKO and DKO mice, and circulating GDF15 concentrations were equally elevated in both groups compared with controls. Thermogenic gene expression in brown fat remained impaired in the double knockouts just as in the single mutants, confirming that GFRAL signaling is not required for the induction of GDF15 secretion or for the local thermogenic changes within brown fat itself.

Under ordinary chow feeding, the receptor turned out to be largely irrelevant to the baseline benefits of the OPA1 deletion. Six-week-old DKO mice weighed the same as their wild-type, OPA1 BKO, and GFRAL KO littermates, with comparable fat mass, lean mass, glucose tolerance, and fasting glucose. Moreover, the compensatory browning of inguinal white adipose tissue, in which white fat depots acquire thermogenic properties and begin expressing the uncoupling protein UCP1, proceeded undiminished in DKO mice. Levels of UCP1 protein in their white fat were elevated to the same degree as in OPA1 BKO animals. This finding dovetails with earlier work showing that the browning response under baseline conditions is driven primarily by FGF21 rather than GDF15, and it establishes that GFRAL signaling is dispensable for this particular adaptation.

The picture changed dramatically when the mice were challenged with a high-fat diet. Over twelve weeks of feeding a diet in which 60 percent of calories came from fat, OPA1 BKO mice once again resisted weight gain, staying leaner than all other groups. GFRAL knockout mice, lacking the stress context, gained weight just like wild-type controls. The DKO animals displayed an intermediate phenotype: they weighed significantly less than wild-type mice at the end of the diet and accumulated less total fat, yet they were substantially heavier and fatter than the OPA1 BKO mice. Fat depots including inguinal and gonadal white adipose tissue told the same story, with DKO mice falling between the two extremes. Indirect calorimetry added a crucial detail: energy expenditure, oxygen consumption, carbon dioxide production, and food intake were statistically indistinguishable across the genotypes, indicating that the partial loss of obesity resistance in DKO mice was not explained by altered caloric intake. The investigators also observed a trend toward attenuated browning of white fat in DKO mice under obesogenic conditions, suggesting that GDF15 acting through GFRAL helps sustain the UCP1-mediated energy expenditure that keeps OPA1 BKO mice lean on a fatty diet.

Even more striking was the dissociation between body weight and metabolic health. Although DKO mice accumulated less fat than wild-type controls, they failed to gain the glucose and liver benefits that make the OPA1 BKO phenotype so remarkable. Glucose tolerance tests and insulin tolerance tests showed that DKO mice were no better than wild-type animals, and their fasting glucose and circulating insulin levels were similarly unimproved. Liver triglyceride content, which is reduced in OPA1 BKO mice, remained at wild-type levels in the double knockouts. This finding implies that GFRAL-mediated signaling may have direct effects on glucose homeostasis, insulin sensitivity, and hepatic lipid metabolism that are independent of the amount of fat the animals carry, although the authors caution that the greater fat mass in DKO mice could itself be sufficient to blunt these improvements. Notably, GFRAL deletion alone produced no changes in body weight, food intake, glucose handling, or liver triglycerides under these experimental conditions, contrasting with some earlier reports and likely reflecting differences in genetic background and diet protocols.

The cold-exposure experiments delivered perhaps the most dramatic result. When mice adapted to 30 degrees Celsius were suddenly shifted to 4 degrees, DKO animals became severely hypothermic, losing the enhanced cold tolerance that characterizes OPA1 BKO mice, while GFRAL knockout mice maintained their core body temperature as well as wild-type controls. This suggests that GFRAL signaling becomes critical for thermoregulation only in the context of mitochondrial stress in brown fat. Surprisingly, the molecular analysis did not reveal an obvious culprit: thermogenic gene expression and UCP1 protein levels in both brown and white fat were similarly altered in OPA1 BKO and DKO mice after cold exposure, and sympathetic activation, estimated by tyrosine hydroxylase levels, did not differ between the two stressed groups. The researchers speculate that GFRAL-dependent, UCP1-independent heat production, such as the futile calcium cycling in skeletal muscle recently linked to GDF15 signaling, may underlie the hypothermia phenotype, though this remains to be tested.

The broader implications are considerable. GDF15 has attracted intense pharmaceutical interest as a potential anti-obesity therapy, and long-acting formulations of the cytokine have shown weight-loss effects extending from mice to monkeys. But a full picture of GFRAL-dependent versus GFRAL-independent actions of GDF15 is essential for designing such therapies, and the new data significantly expand the known reach of the GFRAL pathway. Beyond appetite suppression in the hindbrain, the receptor now appears to modulate energy expenditure, white fat browning, glucose homeostasis, liver lipid handling, and cold-induced thermoregulation, at least in the setting of brown-fat mitochondrial stress. The authors also note an important caveat: because GFRAL was deleted throughout development, it remains possible that remodeling of thermoregulatory neural circuits contributes to the phenotypes observed.

Taken together, the study defines a novel BAT-GDF15-GFRAL axis, a three-node communication system in which stressed brown fat secretes GDF15 as an endocrine signal, the hindbrain receives it through GFRAL, and the brain then orchestrates systemic adaptations that resist obesity and defend body temperature. The discovery that different stress contexts engage this pathway differently, with physiological stress leaving thermoregulation intact while mitochondrial stress makes it indispensable, suggests a layer of regulatory specificity that could be exploited therapeutically. As obesity and its comorbidities continue their global rise, understanding precisely how a signal from burning fat reaches the brainstem and reshapes whole-body metabolism may prove to be more than an elegant piece of physiology; it may point the way toward the next generation of metabolic medicines.

Brown adipose tissue differs fundamentally from white adipose tissue not only in color but in function, primarily through its expression of uncoupling protein 1 (UCP1) that enables heat generation. This thermogenic capacity enables brown fat to expend energy, a process critical for maintaining body temperature and systemic energy balance. Understanding the endogenous mechanisms that modulate BAT activity is therefore a cornerstone in metabolic research. Prior to this study, the molecular pathways shaping brown fat metabolism, especially at the local tissue level, were incompletely characterized. The identification of Neuritin 1 in this context addresses a major knowledge gap, providing fresh insights into the molecular circuitry driving BAT function.

Neuritin 1, previously studied predominantly in the nervous system where it modulates synaptic plasticity and neuronal survival, is now implicated in an entirely different physiology. The research reveals that Neuritin 1 acts as an intrinsic metabolic regulator in brown adipose tissue, influencing metabolic pathways that govern energy expenditure. The authors utilized a combination of transcriptomic analyses, protein expression profiling, and functional assays to demonstrate that Neuritin 1 expression is enriched in BAT compared to other adipose depots and that its presence is dynamically regulated in response to metabolic stressors such as cold exposure.

Mechanistically, Neuritin 1 appears to orchestrate a network of signaling pathways that enhance mitochondrial biogenesis and respiratory capacity within brown adipocytes. Detailed examination revealed that Neuritin 1 positively influences the expression of thermogenic genes and augments mitochondrial oxidative phosphorylation. This effect was demonstrated both in vitro, using cultured brown adipocytes, and in vivo, through genetic mouse models engineered to modulate Neuritin 1 expression. Mice with elevated Neuritin 1 in BAT exhibited increased energy expenditure and resistance to diet-induced obesity, underscoring the protein’s functional relevance.

The study also delved into the molecular underpinnings of Neuritin 1’s action, highlighting its ability to interact with key signaling molecules involved in metabolic regulation, such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). This interaction suggests Neuritin 1 may serve as an upstream modulator that integrates environmental cues and cellular energy demands to fine-tune brown fat’s thermogenic output. Such findings deepen our understanding of how intracellular communication networks coordinate adaptive metabolic responses.

One of the more striking findings was the modulation of Neuritin 1 expression by environmental and physiological stimuli known to activate BAT, such as cold exposure and β-adrenergic signaling. Neuritin 1 levels rose significantly upon cold challenge, correlating temporally with increased thermogenic gene expression. This responsiveness positions Neuritin 1 as a potential molecular switch that enhances brown fat activity in response to external environmental stimuli, providing a compelling link between sensory adaptation and metabolic control.

From a translational perspective, targeting Neuritin 1 or its downstream signaling pathways offers exciting therapeutic potential. The enhancement of BAT function has long been proposed as a strategy to counteract obesity by increasing energy expenditure. However, prior attempts have been hampered by the lack of specific regulators that can be safely modulated. Neuritin 1’s tissue-specific expression and defined role in brown adipose metabolism present a promising target for pharmacological intervention aimed at boosting endogenous thermogenic capacity without systemic side effects.

Moreover, this discovery invites a broader reconsideration of the role of neural factors in metabolic tissues beyond their classical contexts. The crossover between neurobiology and metabolism suggested by Neuritin 1’s dual functionality opens new interdisciplinary vistas for research. It also prompts investigation into whether other neurotrophic factors or neural modulators similarly influence adipose tissue physiology or systemic energy homeostasis, potentially unveiling a wider network of neurometabolic regulators.

The research employed state-of-the-art techniques to dissect Neuritin 1’s role, including loss-of-function and gain-of-function genetic models, advanced metabolomics, and high-resolution imaging of mitochondrial dynamics. These methodologies provided a comprehensive view of how Neuritin 1 impacts cellular bioenergetics and structural integrity of brown adipocytes. Complementary human tissue analyses indicated that Neuritin 1 is also present in human brown fat depots, suggesting translational relevance and the possibility that modulation of this protein could be beneficial in clinical settings.

In addition to metabolic regulation, the study hinted at Neuritin 1’s involvement in brown adipose tissue remodeling and plasticity. Brown fat is known for its remarkable capacity to expand and recruit new thermogenic adipocytes in response to chronic cold or pharmacological stimuli. Neuritin 1 may contribute to this adaptability by influencing adipocyte differentiation and survival, promoting a functional and metabolically active BAT milieu. This dimension adds complexity to the protein’s role and suggests it may support both acute thermogenic responses and longer-term tissue homeostasis.

As global metabolic diseases continue their unchecked rise, fueled by sedentary lifestyles and caloric excess, insights into regulators like Neuritin 1 bring hope for innovative therapies. Current anti-obesity treatments are limited by efficacy or adverse effects, while lifestyle interventions struggle with adherence and sustainability. The therapeutic activation of brown adipose tissue represents a compelling strategy to increase energy expenditure naturally, and discoveries like this pave the way for new drug development paradigms.

The findings also underscore the importance of local tissue regulation in systemic metabolism. It becomes increasingly clear that adipose tissues are not mere fat storage sites but active endocrine and metabolic organs, capable of complex regulatory functions. Neuritin 1 exemplifies this local control—a molecule with specialized, tissue-specific effects that exert broad physiological consequences. This layered understanding may refine future approaches to metabolic disease management, favoring precision medicine approaches targeting specific tissues or cell types.

Looking ahead, several open questions emerge from this study. How exactly does Neuritin 1 interface with other known BAT regulators such as fibroblast growth factor 21 (FGF21) and irisin? Could Neuritin 1 levels serve as biomarkers for brown fat activity or metabolic health? Furthermore, the potential side effects of modulating Neuritin 1 pharmacologically must be thoroughly investigated, given its roles in neuronal function. These are critical considerations as the field moves towards clinical translation.

In sum, the identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue offers a paradigm shift in how scientists and clinicians understand energy metabolism and thermogenesis. This discovery integrates molecular biology with physiological adaptation, highlighting a novel neuro-metabolic nexus that may be harnessed to fight obesity and related metabolic disorders. The work of Sánchez-Feutrie and colleagues thus represents a landmark in metabolic research, with wide-reaching implications for health and disease.

Subject of Research: Brown adipose tissue metabolic regulation and role of Neuritin 1

Article Title: Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue

Article References:

Sánchez-Feutrie, M., Romero, M., Veiga, S.R. et al. Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue.
Nat Commun 16, 7033 (2025). https://doi.org/10.1038/s41467-025-62255-2

Image Credits: AI Generated